Digital Model for Sickle Cell Disease
Sickle Cell Disease
Development/ValidationActive
Key Facts
About Koneksa Health
Koneksa Health is a New York-based digital health innovator founded in 2014, specializing in using digital biomarkers and AI to transform clinical evidence generation. The company offers a multimodal data platform and expert services that help biopharma clients design smarter, faster, and more patient-centric clinical trials. By unlocking novel signals from complex datasets, Koneksa aims to improve trial efficiency, enhance signal detection, and accelerate therapeutic development across neurology, oncology, respiratory, and rare diseases. It operates as a private, revenue-generating platform and services company trusted by industry leaders.
View full company profileTherapeutic Areas
Other Sickle Cell Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ANXV | Annexin Pharmaceuticals | Research |
| Oxbryta® (voxelotor) | Cleo Life Sciences | Approved |
| CT-101 | Cetya Therapeutics | Pre-clinical |
| Endari (L-glutamine oral powder) | Emmaus Life Sciences | Approved |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| ILX-002 | Illexcor Therapeutics | Pre-clinical |
| Epeleuton | Afimmune | Phase 2 |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical or Phase 1 |
| CLY-124 | Cellarity | Phase 1 |
| AB1 | AkiraBio | Pre-clinical |
| Oral Decitabine/Tetrahydrouridine | Novo Nordisk | Phase 2 |